Royalty Pharma sells share of ibrutinib royalties; Australian drug study probed;

@FierceBiotech: Icon signs up to boost Taiwan's stake in drug development. FierceCRO article | Release | Follow @FierceBiotech

@JohnCFierce: If Roche does try to buy Alexion, the company is going to get slaughtered by the analysts. More | Follow @JohnCFierce

@RyanMFierce: CollabRx elbows into software game for gene interpretation. FierceBiotech IT story | Follow @RyanMFierce

@EmilyMFierce: Newly discovered proteins could play role in destroying cancer cells. More from FierceBiotech Research | Follow @EmilyMFierce

> Royalty Pharma sold about 20% of the royalty interest in ibrutinib it recently acquired from Quest Diagnostics ($DGX) to Aisling and Clarus. Release

> Australia's ABC reports that a cancer drug study has been suspended pending an investigation of the science and data that underpin the compound DZ13. Story

Medical Device News

@FierceMedDev: Kona snags ex-SonoSite exec to helm renal denervation. Article | Follow @FierceMedDev

@DamianFierce: Medtronic is spending $200M on a telehealth outfit with an eye on slashing healthcare costs. News | Follow @DamianFierce

@MichaelGFierce: New antivirus system could protect medical devices from infection. Article | Follow @MichaelGFierce

> Agilent, SomaLogic team up on Dx technology. Item

> Montreal's EMcision launches catheters for pancreatic cancer. More

Pharma News

@FiercePharma: Still trending: Pharma professionals feeling angst, but see a few rays of hope. Story | Follow @FiercePharma

@EricPFierce: India's Aurobindo puts sterile injectables unit into a subsidiary to unlock value. Wonder if it will shop it next? Story | Follow @EricPFierce

@CarlyHFierce: Sanofi's statement on the latest bribery allegations in China: Statement | Follow @CarlyHFierce

> Roche chief's comments about deal discipline push shares up. Item

> LAT: Purdue keeps 'risky' OxyContin prescribers' names private. Article

> Sanofi 'confident' about China ops as officials launch bribery probe. Report

CRO News

> Covance offers service to keep contracts under control. Item

> ScinoPharm, Sundia team up in China. Report

> Parexel bets big on the future as revenue swells. Story

> AMRI swings to red despite another sales jump. More

> InVentiv takes aim at blockbusters with biosimilar deal. Article

Biotech IT News

> Medidata to score $287.5M in major financing. News

> CollabRx elbows into software game for gene interpretation. More

> Roche rolls out updated software for next-generation sequencing. Report

> Big Data analysis outfit GNS teams with Inova on predicting preterm birth. Story

> Gene by Gene acquires software upstart Arpeggi. Article

Blog watch: Xconomy's Luke Timmerman concludes that the idea of rewarding scientists with big bonuses for their drug research is a bad idea. Blog

Suggested Articles

When it’s time to go public, most biotech companies for the Nasdaq. Not so for SQZ Biotech, which raised $71 million in its NYSE debut.

The saga of COVID antibody R&D continues as the REGN-COV2 antibody cocktail used by President Donald Trump has been hit by safety concerns.

A Dartmouth-led team proposed a method for targeting and inhibiting the most aggressive cells in breast tumors to improve responses to chemotherapy.